title: Consensus Statement on medication use in multiple sclerosis by the Spanish Society of Neurology's study group for demyelinating diseases.
abstract: Treatments for multiple sclerosis therapy are rapidly evolving. It is believed that new drugs will be approved in the near future, thereby changing current indications for treatment. In this context, the Spanish Society of Neurology's study group on demyelinating diseases, which evaluates medication use in MS, has decided to draw up a consensus statement on the current indications and guidelines for multiple sclerosis treatment.
authors: Servicio de Neurología/Unidad de Neuroinmunología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España. jgarciam.hpth@salud.madrid.org
authors: A
authors: A
authors: García-Merino
authors: O
authors: O
authors: Fernández
authors: X
authors: X
authors: Montalbán
authors: C
authors: C
authors: de Andrés
authors: C
authors: C
authors: Oreja-Guevara
authors: A
authors: A
authors: Rodríguez-Antigüedad
authors: T
authors: T
authors: Arbizu
mesh_terms: D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D013030:Spain
keywords: Drug failure; Drugs; Esclerosis múltiple; Fracaso terapéutico; Fármacos; Lines of therapy; Líneas de tratamiento; Multiple sclerosis; Tratamiento; Treatment